Stem cell transplant was pioneered at the University of Minnesota with the world's first successful donor transplant for malignant lymphoma performed in 1973. The patient was a 16-year old boy who is now 50 years old, married with a son, and living in the Twin Cities. Since then, hematopoietic cell transplantation has become a mainstay of treatment for blood and bone marrow cancers. The University of Minnesota through its Masonic Cancer Center has consistently maintained international leadership in stem cell transplant research and treatment.
Recent stem cell transplant research achievements
McGlave's research team most recently verified the effectiveness of umbilical cord blood transplants. Such transplants can be used in the majority of patients where a sibling is not available to serve as a stem cell donor. This finding now allows transplant physicians to identify donors for the majority of patients requiring hematopoietic cell transplants for treatment of hematologic cancers and diseases. Lead investigators on McGlave's team include University of Minnesota scientists Bruce Blazar, M.D., John Wagner, M.D., and Miller.
Achievements by Miller's research team include finding that favorable NK cell receptor genes in unrelated blood and marrow donors protect against relapse and provide significant relapse-free survival benefit to patients transplanted for treatment of acute myeloid leukemia. Lead investigators on Miller's team include Daniel Weisdorf, M.D., Sarah Cooley, M.D., and Chap Le, Ph.D., with Masonic Cancer Center; Peter Parham, Ph.D., Stanford University, Palo Alto, CA; Elizabeth Trachtenberg, Ph.D., The Children's Hospital Research Institute, Oakland, CA; Steven Marsh, Ph.D., Anthony Nolan Research, London, UK: and John Klein, Ph.D., Medical College of Wisconsin in Milwaukee.
Research to be conducted with new grants
Research projects McGlave and Miller'
|Contact: Nick Hanson|
University of Minnesota